Resultados y vida financieraSalud - Farma - Biotecnología
Inside Information / Other news releases
06/11/2026 07:30
AMFPublicación inmediata
“Company”), a late -stage clinical biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, provides an update on the preliminary findings from the Phase 2a PICASSO clinical…
Press Release
MaaT Pharma Provides an Update on Preliminary
Findings from the Investigator -Sponsored Phase 2a
PICASSO Trial in Metastatic Melanoma
- PICASSO, an investigator -sponsored study conducted by AP -HP in collaboration with INRA e and Gustave Roussy , evaluated the safety of adding MaaT013 (Xervyteg ® ) to ipilimumab and nivolumab in patients with treatment -naïve metastatic melanoma.
- The randomized, placebo -controlled study met its primary objective of assessing the safety and feasibility of administering a microbiome therapeutic to solid tumor patients receiving combination immune checkpoint inhibitor (ICI) therapy , with no statistically significant difference observed between the two arms in the incidence of Grade 3 or higher adverse events.
- The findings support further clinical evaluation of microbiome ecosystem therapies in combination with immune checkpoint inhibitors.
Lyon, France, November 6, 202 6 – 7.30 am CET – MaaT Pharma (EURONEXT: MAAT – the
“Company”), a late -stage clinical biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, provides an update on the preliminary findings from the Phase 2a PICASSO clinical trial, an investigator -sponsored study conducted by AP -HP in collaboration with INRA e and Gustave Roussy evaluating
MaaT013 (Xervyteg ® ) in combination with immune checkpoint inhibitors (ipilimumab and nivolumab) in patients with advanced, unresectable or metastatic melanoma who had not previously received anti -CTLA -4, anti -PD -1 or anti-PD -L1 therapy.
Press Release
This communication follows the publication of study information in the EU Clinical Trials
Information System (CTIS ), as submitted by the PICASSO investigators. The findings reported here are derived exclusively from this CTIS disclosure and should not be considered a final scientific publication of the study results. Full results and analyses will be presented by the P ICASSO investigators at a future scientific congress . Preliminary results are available here in CTIS .
Preliminary findings , based on currently available data extracted from the CTIS submission :
- The study met its primary objective of assessing the safety and feasibility of adding
MaaT013 (Xervyteg ® ) to ipilimumab and nivolumab in treatment -naïve metastatic melanoma. No statistically significant difference was observed in the incidence of